Since the cancer patients contain more serum A-SAA as evidenced by the level of A-SAA monomer and seeding-liable oligomer, the PMCA procedure may further amplify the signals to enhance differences between the HCC and non-cancer groups. The gene discussed is SAA2; the disease is hepatocellular carcinoma.